Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study by Egbert F Smit, Willemijn S M E Theelen, Michiel M Smeenk, Vincent van der Noort, Jeroen M A Hendrikx, Hanieh Abedian Kalkhoran

Get full text